June 22, 2017 / 11:14 AM / 2 months ago

BRIEF-Kalytera Therapeutics says Robert Farrell will assume role of interim CEO

June 22 (Reuters) - Kalytera Therapeutics Inc:

* Kalytera Therapeutics Inc - Robert Farrell, J.D., president and cfo of Kalytera, will assume role of interim chief executive officer

* Kalytera Therapeutics - anticipates it will begin patient enrollment in a phase 2 clinical study evaluating cbd for prevention of gvhd in h2 of 2017

* Kalytera Therapeutics - Andrew L. Salzman, m.d., who previously served as CEO will be leaving company, effective june 21, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below